US5116964A
(en)
*
|
1989-02-23 |
1992-05-26 |
Genentech, Inc. |
Hybrid immunoglobulins
|
US5225538A
(en)
*
|
1989-02-23 |
1993-07-06 |
Genentech, Inc. |
Lymphocyte homing receptor/immunoglobulin fusion proteins
|
US6406697B1
(en)
|
1989-02-23 |
2002-06-18 |
Genentech, Inc. |
Hybrid immunoglobulins
|
US5766883A
(en)
*
|
1989-04-29 |
1998-06-16 |
Delta Biotechnology Limited |
Polypeptides
|
ATE92107T1
(de)
*
|
1989-04-29 |
1993-08-15 |
Delta Biotechnology Ltd |
N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
|
GB8909916D0
(en)
*
|
1989-04-29 |
1989-06-14 |
Delta Biotechnology Ltd |
Polypeptides
|
GB8927480D0
(en)
*
|
1989-12-05 |
1990-02-07 |
Delta Biotechnology Ltd |
Mutant fungal strain detection and new promoter
|
US5993805A
(en)
*
|
1991-04-10 |
1999-11-30 |
Quadrant Healthcare (Uk) Limited |
Spray-dried microparticles and their use as therapeutic vehicles
|
FR2686899B1
(fr)
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
US5698517A
(en)
*
|
1994-03-21 |
1997-12-16 |
University Of Hawaii, Office Of Technology Transfer And Economic Development |
Thyroxin-binding HSA fragments
|
US5674842A
(en)
*
|
1994-10-26 |
1997-10-07 |
Health Research, Incorporated |
Growth inhibitory peptide
|
US7820798B2
(en)
|
1994-11-07 |
2010-10-26 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
US5723125A
(en)
*
|
1995-12-28 |
1998-03-03 |
Tanox Biosystems, Inc. |
Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
|
GB9526733D0
(en)
|
1995-12-30 |
1996-02-28 |
Delta Biotechnology Ltd |
Fusion proteins
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
EP0947581A4
(en)
*
|
1996-08-08 |
2004-07-28 |
Mitsubishi Pharma Corp |
CULTURAL MEDIUM AND ITS USE.
|
US6274305B1
(en)
|
1996-12-19 |
2001-08-14 |
Tufts University |
Inhibiting proliferation of cancer cells
|
GB9815909D0
(en)
|
1998-07-21 |
1998-09-16 |
Btg Int Ltd |
Antibody preparation
|
WO2000022112A1
(en)
|
1998-10-13 |
2000-04-20 |
The University Of Georgia Research Foundation, Inc. |
Stabilized bioactive peptides and methods of identification, synthesis and use
|
US20030190740A1
(en)
|
1998-10-13 |
2003-10-09 |
The University Of Georgia Research Foundation, Inc |
Stabilized bioactive peptides and methods of identification, synthesis, and use
|
US6946134B1
(en)
|
2000-04-12 |
2005-09-20 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
AU2001259063A1
(en)
|
2000-04-12 |
2001-10-30 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US20050100991A1
(en)
*
|
2001-04-12 |
2005-05-12 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US20030031675A1
(en)
|
2000-06-06 |
2003-02-13 |
Mikesell Glen E. |
B7-related nucleic acids and polypeptides useful for immunomodulation
|
EP2281843B1
(en)
|
2000-06-16 |
2016-10-12 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to BLyS
|
WO2002022685A2
(en)
*
|
2000-09-11 |
2002-03-21 |
Kufe Donald W |
Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom
|
IL155812A0
(en)
|
2000-12-07 |
2003-12-23 |
Lilly Co Eli |
Glp-1 fusion proteins
|
US20020110841A1
(en)
*
|
2000-12-22 |
2002-08-15 |
KUFE Donald W. |
Regulation of cell growth by MUC1
|
US20050244931A1
(en)
*
|
2001-04-12 |
2005-11-03 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US7507413B2
(en)
|
2001-04-12 |
2009-03-24 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US20060084794A1
(en)
*
|
2001-04-12 |
2006-04-20 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US20050054051A1
(en)
*
|
2001-04-12 |
2005-03-10 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
DK1385864T3
(da)
|
2001-04-13 |
2010-08-16 |
Human Genome Sciences Inc |
Anti-VEGF-2-antistoffer
|
DK1572874T3
(da)
|
2001-05-25 |
2013-12-16 |
Human Genome Sciences Inc |
Antistoffer, der immunospecifikt binder til TRAIL receptorer
|
WO2003030821A2
(en)
*
|
2001-10-05 |
2003-04-17 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
CN105131104B
(zh)
|
2001-10-10 |
2018-11-16 |
诺和诺德公司 |
肽的重构和糖缀合
|
DK1578771T3
(da)
|
2001-10-10 |
2013-06-10 |
Novo Nordisk As |
Remodellering og glycokonjugering af peptider
|
WO2003059934A2
(en)
*
|
2001-12-21 |
2003-07-24 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
EP1463751B1
(en)
*
|
2001-12-21 |
2013-05-22 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
US20080194481A1
(en)
|
2001-12-21 |
2008-08-14 |
Human Genome Sciences, Inc. |
Albumin Fusion Proteins
|
EP1471928A1
(en)
|
2002-02-07 |
2004-11-03 |
Delta Biotechnology Limited |
Hiv inhibiting proteins
|
US20060002935A1
(en)
|
2002-06-28 |
2006-01-05 |
Domantis Limited |
Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
|
GB0217033D0
(en)
|
2002-07-23 |
2002-08-28 |
Delta Biotechnology Ltd |
Gene and polypeptide sequences
|
WO2004041865A2
(en)
|
2002-11-08 |
2004-05-21 |
Ablynx N.V. |
Stabilized single domain antibodies
|
EP1594530A4
(en)
|
2003-01-22 |
2006-10-11 |
Human Genome Sciences Inc |
HYBRID PROTEINS OF ALBUMIN
|
EP2338333B1
(en)
|
2003-04-09 |
2017-09-06 |
ratiopharm GmbH |
Glycopegylation methods and proteins/peptides produced by the methods
|
US20080090770A1
(en)
*
|
2003-04-11 |
2008-04-17 |
Belmares Michael P |
Modulation of Muc1 Mediated Signal Transduction
|
US8129506B2
(en)
*
|
2003-10-24 |
2012-03-06 |
Genzyme Corporation |
Modulation of the interaction of MUC1 with MUC1 ligands
|
EP1729795B1
(en)
|
2004-02-09 |
2016-02-03 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
WO2005082458A1
(en)
*
|
2004-02-23 |
2005-09-09 |
Genzyme Corporation |
Muc1 antagonist enhancement of death receptor ligand-induced apoptosis
|
US7973139B2
(en)
|
2004-03-26 |
2011-07-05 |
Human Genome Sciences, Inc. |
Antibodies against nogo receptor
|
EP1799713B1
(en)
|
2004-09-23 |
2014-11-05 |
VasGene Therapeutics, Inc. |
Polypeptide compounds for inhibiting angiogenesis and tumor growth
|
CN101724071A
(zh)
|
2004-10-08 |
2010-06-09 |
杜门蒂斯有限公司 |
抗肿瘤坏死因子受体1的单域抗体及其使用方法
|
CA2626082C
(en)
|
2005-10-13 |
2017-04-11 |
Human Genome Sciences, Inc. |
Methods and compositions for use in treatment of patients with autoantibody positive disease
|
JP5256199B2
(ja)
|
2006-08-07 |
2013-08-07 |
テヴァ バイオファーマシューティカルズ ユーエスエー,インコーポレーティッド |
アルブミン−インスリン融合タンパク質
|
EP2069396B1
(en)
|
2006-09-08 |
2015-10-21 |
Ambrx, Inc. |
Modified human plasma polypeptide or fc scaffolds and their uses
|
EP2423220B1
(en)
|
2007-01-30 |
2015-04-29 |
Epivax, Inc. |
Regulatory t cell epitopes, compositions and uses thereof
|
US7871784B2
(en)
*
|
2007-02-02 |
2011-01-18 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions relating to the regulation of apoptosis by MUC1 and BH3-containing proapoptotic proteins
|
US7972870B2
(en)
|
2007-02-02 |
2011-07-05 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions relating to the regulation of MUC1 by HSF1 and STAT3
|
CA2683772C
(en)
|
2007-04-12 |
2020-06-16 |
Peter Wilhelmus Maria Hermans |
New virulence factors of streptococcus pneumoniae
|
KR101460953B1
(ko)
|
2007-04-17 |
2014-11-13 |
스티칭 디엔스트 랜드보위쿤디그 온데조에크 |
비-포유동물 글리코실트랜스퍼라제의 발현에 의한 식물에서의 포유동물형 글리코실화
|
CA2685596A1
(en)
|
2007-05-02 |
2008-11-13 |
Ambrx, Inc. |
Modified interferon beta polypeptides and their uses
|
CA2688433A1
(en)
|
2007-06-06 |
2008-12-11 |
Domantis Limited |
Methods for selecting protease resistant polypeptides
|
TWI489993B
(zh)
|
2007-10-12 |
2015-07-01 |
Novartis Ag |
骨硬化素(sclerostin)抗體組合物及使用方法
|
NZ603812A
(en)
|
2007-11-20 |
2014-06-27 |
Ambrx Inc |
Modified insulin polypeptides and their uses
|
NZ591235A
(en)
|
2008-07-23 |
2012-07-27 |
Ambrx Inc |
Modified bovine g-csf polypeptides comprising non natural amino acid and their uses treating infections such as mastitis
|
EP2174664A1
(en)
|
2008-10-07 |
2010-04-14 |
Stichting Katholieke Universiteit, more particularly the Radboud University Nijmegen Medical Centre |
New virulence factors of Streptococcus pneumoniae
|
IT1392551B1
(it)
*
|
2008-11-25 |
2012-03-09 |
Bioindustry Park Del Canavese S P A |
Biomarcatori per la diagnosi e per rilevare la progressione di malattie neurodegenerative, in particolare della sclerosi laterale amiotrofica
|
EP2364326B1
(en)
|
2008-12-05 |
2018-07-04 |
Glaxo Group Limited |
Methods for selecting protease resistant polypeptides
|
US9493545B2
(en)
|
2009-02-11 |
2016-11-15 |
Albumedix A/S |
Albumin variants and conjugates
|
CN102405236A
(zh)
|
2009-02-19 |
2012-04-04 |
葛兰素集团有限公司 |
改进的抗-tnfr1多肽,抗体可变结构域和拮抗剂
|
CN102414223A
(zh)
|
2009-04-27 |
2012-04-11 |
诺瓦提斯公司 |
对IL12受体β亚基特异的治疗性抗体的组合物和方法
|
NO2424895T3
(hu)
|
2009-04-27 |
2018-02-03 |
|
|
CA2768460A1
(en)
|
2009-07-16 |
2011-01-20 |
Glaxo Group Limited |
Antagonists, uses & methods for partially inhibiting tnfr1
|
WO2011029823A1
(en)
|
2009-09-09 |
2011-03-17 |
Novartis Ag |
Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
|
CA2777312A1
(en)
|
2009-10-27 |
2011-05-05 |
Inusha De Silva |
Stable anti-tnfr1 polypeptides, antibody variable domains & antagonists
|
GB0919054D0
(en)
|
2009-10-30 |
2009-12-16 |
Isis Innovation |
Treatment of obesity
|
US8748380B2
(en)
|
2009-10-30 |
2014-06-10 |
Novozymes Biopharma Dk A/S |
Albumin variants
|
GB0919837D0
(en)
|
2009-11-13 |
2009-12-30 |
Isis Innovation |
Method of treatment and screening method
|
CN104017063A
(zh)
|
2009-12-21 |
2014-09-03 |
Ambrx公司 |
经过修饰的猪促生长素多肽和其用途
|
NZ600361A
(en)
|
2009-12-21 |
2014-06-27 |
Ambrx Inc |
Modified bovine somatotropin polypeptides and their uses
|
EP2538971B1
(en)
|
2010-02-23 |
2015-10-28 |
Stichting Katholieke Universiteit |
Combination vaccine for streptococcus
|
US10233228B2
(en)
|
2010-04-09 |
2019-03-19 |
Albumedix Ltd |
Albumin derivatives and variants
|
MY162837A
(en)
|
2010-08-17 |
2017-07-31 |
Ambrx Inc |
Modified relaxin polypeptides and their uses
|
JP2013543384A
(ja)
|
2010-10-05 |
2013-12-05 |
ノバルティス アーゲー |
抗−il12rベータ1抗体ならびに自己免疫性および炎症性疾患の処置おけるその使用
|
JP6190723B2
(ja)
|
2010-12-01 |
2017-08-30 |
アルダーバイオ ホールディングス エルエルシー |
抗ngf組成物およびその使用
|
ES2676878T3
(es)
|
2011-03-03 |
2018-07-25 |
Zymeworks Inc. |
Diseño de armazón de heteromultímero multivalente y constructos
|
PT2707391T
(pt)
|
2011-05-13 |
2018-02-06 |
Inserm Institut National De La Santa© Et De La Rech Ma©Dicale |
Anticorpos contra her3
|
EP2709663B1
(en)
|
2011-05-20 |
2019-03-20 |
AlderBio Holdings LLC |
Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
|
AU2012258976B8
(en)
|
2011-05-20 |
2017-07-20 |
H. Lundbeck A/S |
Use of anti-CGRP or anti-CGRP-R antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
|
HUE054437T2
(hu)
|
2011-05-20 |
2021-09-28 |
H Lundbeck As |
Anti-CGRP készítmények és alkalmazásuk
|
AU2012273954A1
(en)
|
2011-06-22 |
2014-01-09 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Anti-Axl antibodies and uses thereof
|
ES2677367T3
(es)
|
2011-06-22 |
2018-08-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anticuerpos anti-Axl y usos de los mismos
|
CN103930440A
(zh)
|
2011-07-01 |
2014-07-16 |
拜耳知识产权有限责任公司 |
松弛素融合多肽及其用途
|
JP6472999B2
(ja)
|
2011-07-01 |
2019-02-20 |
ノバルティス アーゲー |
代謝障害を治療するための方法
|
CA2840944A1
(en)
|
2011-07-08 |
2013-01-17 |
Bayer Intellectual Property Gmbh |
Fusion proteins releasing relaxin and uses thereof
|
WO2013022058A1
(ja)
*
|
2011-08-10 |
2013-02-14 |
ニプロ株式会社 |
ビリルビン排泄促進剤
|
US20140315817A1
(en)
|
2011-11-18 |
2014-10-23 |
Eleven Biotherapeutics, Inc. |
Variant serum albumin with improved half-life and other properties
|
AU2013234299B2
(en)
|
2012-03-16 |
2017-06-22 |
Albumedix Ltd. |
Albumin variants
|
EP2851429B1
(en)
|
2012-05-18 |
2019-07-24 |
Adda Biotech Inc. |
Protein and protein conjugate for diabetes treatment, and applications thereof
|
WO2014012082A2
(en)
|
2012-07-13 |
2014-01-16 |
Zymeworks Inc. |
Multivalent heteromultimer scaffold design an constructs
|
JOP20200308A1
(ar)
|
2012-09-07 |
2017-06-16 |
Novartis Ag |
جزيئات إرتباط il-18
|
MX2015005363A
(es)
|
2012-11-08 |
2015-11-06 |
Novozymes Biopharma Dk As |
Variantes de albumina.
|
WO2015198217A2
(en)
|
2013-02-08 |
2015-12-30 |
Novartis Ag |
Compositions and methods for long-acting antibodies targeting il-17
|
SG11201505330QA
(en)
|
2013-02-08 |
2015-08-28 |
Novartis Ag |
Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders
|
EP2968587A2
(en)
|
2013-03-13 |
2016-01-20 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
|
US20150017166A1
(en)
|
2013-07-03 |
2015-01-15 |
Alderbio Holdings Llc |
Regulation of glucose metabolism using anti-cgrp antibodies
|
TN2016000057A1
(en)
|
2013-08-14 |
2017-07-05 |
Novartis Ag |
Methods of treating sporadic inclusion body myositis
|
PL3066124T4
(pl)
|
2013-11-07 |
2021-08-16 |
Inserm - Institut National De La Santé Et De La Recherche Médicale |
Neuregulina-allosteryczne przeciwciała przeciwko ludzkiemu her3
|
EP3077008B1
(en)
|
2013-12-06 |
2023-10-04 |
Jie Han |
Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
|
ES2947566T3
(es)
*
|
2013-12-23 |
2023-08-11 |
Covalab |
Sustratos de Mtg para la conjugación covalente de compuestos
|
TW201622746A
(zh)
|
2014-04-24 |
2016-07-01 |
諾華公司 |
改善或加速髖部骨折術後身體復原之方法
|
EP3157947A1
(en)
|
2014-06-23 |
2017-04-26 |
Novartis AG |
Hsa-gdf-15 fusion polypeptide and use thereof
|
RU2730668C2
(ru)
|
2014-11-19 |
2020-08-24 |
Аксон Ньюросайенс Се |
Гуманизированные тау-антитела при болезни альцгеймера
|
US10398774B2
(en)
|
2014-12-09 |
2019-09-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Human monoclonal antibodies against AXL
|
WO2016100838A2
(en)
|
2014-12-19 |
2016-06-23 |
Alder Biopharmaceuticals, Inc. |
Humanized anti-acth antibodies and use thereof
|
NL2014148B1
(en)
|
2015-01-16 |
2017-01-05 |
Univ Erasmus Med Ct Rotterdam |
Combination vaccine for camelids.
|
WO2016135041A1
(en)
|
2015-02-26 |
2016-09-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Fusion proteins and antibodies comprising thereof for promoting apoptosis
|
RU2757417C2
(ru)
|
2015-05-19 |
2021-10-15 |
Йейл Юниверсити |
Композиции для лечения патологических состояний кальцификации и способы их применения
|
ES2898023T3
(es)
|
2015-05-22 |
2022-03-03 |
Inst Nat Sante Rech Med |
Fragmentos de anticuerpos monoclonales humanos que inhiben tanto la actividad catalítica de Cath-D como su unión al receptor LRP1
|
CA2993009A1
(en)
|
2015-07-31 |
2017-02-09 |
Research Institute At Nationwide Children's Hospital |
Peptides and antibodies for the removal of biofilms
|
CA2989966C
(en)
|
2015-08-20 |
2024-04-30 |
Albumedix A/S |
Albumin variants and conjugates
|
WO2017066719A2
(en)
|
2015-10-14 |
2017-04-20 |
Research Institute At Nationwide Children's Hospital |
Hu specific interfering agents
|
US11014980B2
(en)
|
2015-10-30 |
2021-05-25 |
The Regents Of The University Of California |
Transforming growth factor-beta-responsive polypeptides and their methods for use
|
JP6946304B2
(ja)
|
2015-12-22 |
2021-10-06 |
ノバルティス アーゲー |
増殖分化因子15(gdf−15)を使用して代謝障害を処置するまたは軽快させる方法
|
CN114907483A
(zh)
|
2016-03-22 |
2022-08-16 |
国家医疗保健研究所 |
人源化抗claudin-1抗体及其用途
|
JP7116685B2
(ja)
|
2016-04-15 |
2022-08-10 |
エイチ. ルンドベック アー/エス |
ヒト化抗pacap抗体及びそれらの使用
|
JP7219207B2
(ja)
|
2016-07-29 |
2023-02-07 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
腫瘍関連マクロファージを標的化する抗体及びその使用
|
US11701384B2
(en)
|
2016-09-02 |
2023-07-18 |
The Regents Of The University Of California |
Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments
|
JP7514621B2
(ja)
|
2017-01-04 |
2024-07-11 |
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル |
Dnabiiワクチンおよび強化された活性を有する抗体
|
AU2018206560A1
(en)
|
2017-01-04 |
2019-07-18 |
Research Institute At Nationwide Children's Hospital |
Antibody fragments for the treatment of biofilm-related disorders
|
JP2020510432A
(ja)
|
2017-03-02 |
2020-04-09 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Nectin−4への特異性を有する抗体及びその使用
|
WO2018170178A1
(en)
|
2017-03-15 |
2018-09-20 |
Research Institute At Nationwide Children's Hospital |
Composition and methods for disruption of bacterial biofilms without accompanying inflammation
|
US10982000B2
(en)
|
2017-03-24 |
2021-04-20 |
Novartis Ag |
Methods for treating and/or reducing the likelihood of heart failure by administering anti-activin receptor type II (anti-ActRII) antibody
|
UY37758A
(es)
|
2017-06-12 |
2019-01-31 |
Novartis Ag |
Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
|
AU2018292579A1
(en)
|
2017-06-28 |
2019-12-05 |
Novartis Ag |
Methods for preventing and treating urinary incontinence
|
CN111727075B
(zh)
|
2017-11-27 |
2024-04-05 |
普渡制药公司 |
靶向人组织因子的人源化抗体
|
EP3552631A1
(en)
|
2018-04-10 |
2019-10-16 |
Inatherys |
Antibody-drug conjugates and their uses for the treatment of cancer
|
US20220047701A1
(en)
|
2018-09-10 |
2022-02-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combination of her2/neu antibody with heme for treating cancer
|
CN112771074A
(zh)
|
2018-10-05 |
2021-05-07 |
国家儿童医院研究所 |
用于酶促破坏细菌生物膜的组合物和方法
|
EP3914282A1
(en)
|
2019-01-25 |
2021-12-01 |
Ospedale San Raffaele S.r.l. |
Inhibitor of dux4 and uses thereof
|
US20220177558A1
(en)
|
2019-03-25 |
2022-06-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Treatment of taupathy disorders by targeting new tau species
|
WO2020250159A1
(en)
|
2019-06-12 |
2020-12-17 |
Novartis Ag |
Natriuretic peptide receptor 1 antibodies and methods of use
|
EP4361171A2
(en)
|
2019-07-08 |
2024-05-01 |
Research Institute at Nationwide Children's Hospital |
Antibody compositions for disrupting biofilms
|
EP4034560A1
(en)
|
2019-09-27 |
2022-08-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-müllerian inhibiting substance antibodies and uses thereof
|
WO2021058729A1
(en)
|
2019-09-27 |
2021-04-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-müllerian inhibiting substance type i receptor antibodies and uses thereof
|
CN115175680A
(zh)
|
2019-10-18 |
2022-10-11 |
加利福尼亚大学董事会 |
Plxdc激活剂及其用于治疗血管病症的用途
|
US20230040928A1
(en)
|
2019-12-09 |
2023-02-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity to her4 and uses thereof
|
CN114929731A
(zh)
|
2020-01-10 |
2022-08-19 |
国家医疗保健研究所 |
Rspo1蛋白及其用途
|
AU2020202454A1
(en)
|
2020-04-06 |
2021-10-21 |
H. Lundbeck A/S |
Treatment of most bothersome symptom (MBS) associated with migraine using anti-CGRP antibodies
|
JP2023525053A
(ja)
|
2020-05-12 |
2023-06-14 |
インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) |
皮膚t細胞リンパ腫及びtfh由来リンパ腫を処置する新しい方法
|
CN115884986A
(zh)
|
2020-06-29 |
2023-03-31 |
Inserm(法国国家健康医学研究院) |
抗蛋白s单域抗体和包含其的多肽
|
US11739166B2
(en)
|
2020-07-02 |
2023-08-29 |
Davol Inc. |
Reactive polysaccharide-based hemostatic agent
|
EP4259661A1
(en)
|
2020-12-14 |
2023-10-18 |
Novartis AG |
Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof
|
IL308134A
(en)
|
2021-06-22 |
2023-12-01 |
Novartis Ag |
BISPECIFIC ANTIBODIES FOR USE IN THE TREATMENT OF HIDRADENITIS SUPPURATIVA
|
AU2022311529A1
(en)
|
2021-07-15 |
2024-01-25 |
Centre National De La Recherche Scientifique (Cnrs) |
Recombinant variants of r-spondin proteins and their use
|
EP4392447A1
(en)
|
2021-08-27 |
2024-07-03 |
H. Lundbeck A/S |
Treatment of cluster headache using anti-cgrp antibodies
|
WO2023170247A1
(en)
|
2022-03-11 |
2023-09-14 |
Mablink Bioscience |
Antibody-drug conjugates and their uses
|
TW202405009A
(zh)
|
2022-03-30 |
2024-02-01 |
瑞士商諾華公司 |
使用抗利尿鈉肽受體1(npr1)抗體治療障礙之方法
|
WO2024052503A1
(en)
|
2022-09-08 |
2024-03-14 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to ltbp2 and uses thereof
|
WO2024056668A1
(en)
|
2022-09-12 |
2024-03-21 |
Institut National de la Santé et de la Recherche Médicale |
New anti-itgb8 antibodies and its uses thereof
|
EP4389762A1
(en)
|
2022-12-23 |
2024-06-26 |
Ospedale San Raffaele S.r.l. |
Inhibitors of dux4 activity and their use in therapy.
|